Royalty Report: Drugs, Biotechnology, Therapeutic – Collection: 203467

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Biotechnology
  • Therapeutic
  • Medical
  • Device
  • Diagnostic

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203467

License Grant
With the assignment to the Assignee of Denmark, the agreement transfers all right, title and interest to the Assigned Technology in the Territory to Assignee.

For the call option, Assignee shall have the option, until sixty (60) Business Days after the Interim Analysis Date, to include the Republic of China in the Territory by having the Call Option Letter signed and executed by Assignor.

Assignee shall have the exclusive right under the Assigned Technology and the Product Trademarks to market, sell, offer to sell, use, import and export, distribute and license Products in the Territory, and submit for approval for or amendment of Marketing Authorization for the Product in the Territory.

For Assignees manufacturing rights, beginning at the earlier of three (3) years from the date of the First Commercial Sale in the Territory or Assignor’s breach of its obligations of supply of Product, in a period exceeding 2 months, Assignee shall have the exclusive right to manufacture, or have manufactured, Product for use in the Territory.

For the Dossier, the Dossier(s) shall be the sole property of Assignee, and Assignor hereby assigns by way of future assignment any rights in or to any amendments or modifications to, or translations of, the Dossiers which it may affect or which may be affected on its behalf, in connection with its use of the Dossiers under the terms of this Agreement; provided, however, that Assignor shall have reasonable access to and use of the Dossiers for Assignor’s use in seeking Marketing Authorizations outside the Territory.

Assignor hereby grants to Assignee a non-exclusive right and license to reference any Marketing Authorizations under the control of Assignor for Products outside the Territory for the purpose of obtaining Marketing Authorization of Products in one or more countries in the Territory.

Assignee shall own all rights in Dossiers, Marketing Authorizations in the Territory, Product and Scientific Data, and the information and data contained therein.

License Property
Assignor is a pharmaceutical development company currently specializing in the development of blood substitution products and owns certain rights to the Product.

The Product means all injectable fluorochemical emulsions capable of transporting oxygen in therapeutic effective amounts in the bloodstream for all medical uses, including without limitation, a product existing as of the Effective Date having a composition agreed upon by the Parties and set out in the Specifications, Existing Product, that the making, using, offering for sale, or selling of which without a license or assignment would infringe a Valid Claim of a patent within the Assigned Patents, is developed using the Assigned Technology, and/or is a modification or change in the formula of the Existing Product.

The patents include: Brominated Perfluorocarbon Emulsions for Internal Animal Use for Contrast Enhancement and Oxygen Transport/ LONG, and, AmphAssigned Technologyhilic Fluorine Derivatives with Telomeric Structures; Preparation Procedure and Biomedical Applications / PA VIA, PUCCI, RlESS, ZARIF, and related foreign patents.

Field of Use
Assignee is a pharmaceutical company possessing expertise in the development and commercialization of pharmaceutical products.  The product is any fluorochemical emulsion with approved indications and is for all medical uses.

OXYGENT (perflubron emulsion) is an intravascular oxygen delivery agent to temporarily augment oxygen delivery in surgical and other patients at risk of acute tissue oxygen deficit. It will be used as a temporary oxygen carrier to provide oxygen to tissues during elective surgeries where substantial blood loss is anticipate.

IPSCIO Record ID: 1451

License Grant
The Licensor granted Licensee, a subsidiary, an exclusive right and license to use the patents and know-how relating to the Licensor's Oxygent(TM) technology to market, sell and distribute products incorporating the Licensor's Oxygent(TM) technology in a territory consisting of North America and the countries commonly referred to as the European Union (the Territory). In addition, under the License the Licensor granted Licensee an exclusive right to manufacture products incorporating the Licensor's Oxygent(TM) technology anywhere in the world for sale and distribution in the Territory.
License Property
OXYGENT (perflubron emulsion) is an intravascular oxygen delivery system to temporarily augment oxygen delivery in surgical and other patients at risk of acute tissue oxygen deficit. It will be used as a temporary oxygen carrier to provide oxygen to tissues during elective surgeries where substantial blood loss is anticipated. It is estimated that in excess of three million patients annually in the United States may receive one or more units of blood during elective surgeries, including, for example, cardiovascular, orthopedic, and general surgical procedures. An oxygen carrier could be used instead of blood for a portion of these patients. The OXYGENT dose for surgical applications is expected to provide the equivalent oxygen delivery of at least two units of red blood cells.
Field of Use
The Field of Use relates to the healthcare market in the pharmaceutical industry.

IPSCIO Record ID: 3608

License Grant
Assignor, an individual, desires to sell, assign, transfer and convey to Assignee, its successors and assigns, Assignor's entire right, title and interest throughout the world in and to the Patent Application and patents issuing thereon to the full end of the term or terms of any said patents.
License Property
Assignor has made certain inventions relating to chimeric peptides.

Product shall mean all products, drugs, diagnostic reagents, diagnostic methods, therapeutic agents and therapeutic methods covered in whole or in part by a Valid Claim contained in any Patent.

Field of Use
Inventions and patent applications relate to the use of chimeric peptides for the treatment of Alzheimer’s disease.

IPSCIO Record ID: 738

License Grant
Entered into by and between the Denmark Assignor and the Assignee to acquire ownership of the Assigned Patents; and Assignor desires to obtain a certain license from Assignee to the Assigned Patents. As an inducement to Denmark Assignor to execute this Patent Assignment Agreement, Assignee hereby grants to Assignor a royalty-bearing, worldwide, exclusive (even as to Assignee) license (with the right to sublicense) to use the inventions, ideas and information embodied in the Assigned Patents to develop, make, use and sell products intended solely for use as reagents or products and methods intended solely for use in testing for and diagnosing conditions in humans, animals or organisms, as well as products and methods intended for predicting or testing the effect of treatment of Conditions in humans or animals.
License Property
The assigned Patents include: Hydroxymethyl substituted RNA oligonucleotides and RNA complexes.
Field of Use
For use in testing for and diagnosing conditions in humans, animals or organisms.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.